MCID: SKN022
MIFTS: 46

Skin Squamous Cell Carcinoma

Categories: Cancer diseases, Skin diseases

Aliases & Classifications for Skin Squamous Cell Carcinoma

MalaCards integrated aliases for Skin Squamous Cell Carcinoma:

Name: Skin Squamous Cell Carcinoma 12 14
Squamous Cell Carcinoma of Skin 12 69
Epidermoid Skin Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3151
NCIt 46 C4819
SNOMED-CT 64 254651007
UMLS 69 C0553723

Summaries for Skin Squamous Cell Carcinoma

Disease Ontology : 12 A skin carcinoma that has material basis in squamous cells.

MalaCards based summary : Skin Squamous Cell Carcinoma, also known as squamous cell carcinoma of skin, is related to palmoplantar hyperkeratosis with squamous cell carcinoma of skin and 46,xx sex reversal and pseudovascular skin squamous cell carcinoma. An important gene associated with Skin Squamous Cell Carcinoma is HRAS (HRas Proto-Oncogene, GTPase), and among its related pathways/superpathways are TGF-Beta Pathway and PI3K-Akt signaling pathway. The drugs Fluorouracil and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include skin, kidney and lymph node, and related phenotypes are endocrine/exocrine gland and hematopoietic system

Related Diseases for Skin Squamous Cell Carcinoma

Diseases related to Skin Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 47)
# Related Disease Score Top Affiliating Genes
1 palmoplantar hyperkeratosis with squamous cell carcinoma of skin and 46,xx sex reversal 12.5
2 pseudovascular skin squamous cell carcinoma 12.1
3 epidermodysplasia verruciformis 11.4
4 anal margin squamous cell carcinoma 11.1
5 squamous cell carcinoma 10.7
6 plantar wart 10.6 IFNA1 TP53
7 squamous cell carcinoma of the oropharynx 10.4 IL10 TP53
8 vulvar intraepithelial neoplasia 10.4 BIRC5 TP53
9 central nervous system lymphoma 10.3 IL10 MGMT TP53
10 microphthalmia with limb anomalies 10.3 IFNA1 STAT1 STAT2
11 bladder transitional cell papilloma 10.3 BIRC5 TP53
12 acquired immunodeficiency syndrome 10.3 IFNA1 IL10 TP53
13 dengue hemorrhagic fever 10.2 IL10 STAT1 STAT2
14 mouth disease 10.2 IFNA1 IL10 STAT1
15 fanconi anemia, complementation group c 10.1 IFNA1 STAT1
16 nevus of ota 10.1 BRAF TP53
17 cerebellar astrocytoma 10.0 BRAF TP53
18 measles 10.0 IFNA1 STAT1 STAT2
19 colorectal adenoma 10.0 HRAS MGMT TP53
20 hyperplastic polyposis syndrome 9.9 BRAF TP53
21 cell type cancer 9.9 HRAS MGMT TP53
22 pleomorphic xanthoastrocytoma 9.9 BRAF MGMT TP53
23 giant cell glioblastoma 9.9 BRAF MGMT TP53
24 medulloblastoma 9.7
25 muir-torre syndrome 9.7
26 xeroderma pigmentosum, variant type 9.7
27 basal cell carcinoma 1 9.7
28 melanoma 9.7
29 basal cell carcinoma 9.7
30 papilloma 9.7
31 cystic teratoma 9.7
32 teratoma 9.7
33 cellulitis 9.7
34 porokeratosis 9.7
35 spindle cell carcinoma 9.7
36 spitz nevus 9.6 BRAF HRAS TP53
37 colorectal adenocarcinoma 9.6 BRAF HRAS TP53
38 bladder urothelial carcinoma 9.6 BRAF HRAS TP53
39 lip cancer 9.6 BRAF TP53
40 differentiated thyroid carcinoma 9.6 BRAF HRAS TP53
41 melanoma, cutaneous malignant 1 9.4 BRAF HRAS MGMT TP53
42 pilocytic astrocytoma 9.4 BRAF HRAS MGMT
43 lung squamous cell carcinoma 9.4 BRAF HRAS TP53
44 lung cancer susceptibility 3 9.4 BIRC5 BRAF HRAS TP53
45 glioblastoma multiforme 9.4 BRAF HRAS MGMT TP53
46 glioblastoma 9.4 BRAF HRAS MGMT TP53
47 adenocarcinoma 9.3 BIRC5 BRAF HRAS TP53

Graphical network of the top 20 diseases related to Skin Squamous Cell Carcinoma:



Diseases related to Skin Squamous Cell Carcinoma

Symptoms & Phenotypes for Skin Squamous Cell Carcinoma

MGI Mouse Phenotypes related to Skin Squamous Cell Carcinoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.02 RARRES2 BRAF STAT1 HRAS TP53 IL10
2 hematopoietic system MP:0005397 10 RARRES2 BRAF STAT1 CD151 STAT2 TNFAIP8L2
3 homeostasis/metabolism MP:0005376 9.93 RARRES2 BRAF STAT1 CD151 TNFAIP8L2 HRAS
4 integument MP:0010771 9.56 BRAF STAT1 CD151 HRAS TP53 IL10
5 neoplasm MP:0002006 9.28 STAT1 CD151 EIF4E HRAS TP53 IL10

Drugs & Therapeutics for Skin Squamous Cell Carcinoma

Drugs for Skin Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 98)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluorouracil Approved Phase 4,Phase 2 51-21-8 3385
2
Triamcinolone Approved, Vet_approved Phase 4,Phase 2 124-94-7 31307
3
Acitretin Approved Phase 4,Phase 2 55079-83-9 5284513 6437841
4 Antimetabolites Phase 4,Phase 2
5 Antimetabolites, Antineoplastic Phase 4,Phase 2
6 Dermatologic Agents Phase 4,Phase 2,Phase 1,Early Phase 1
7 Immunosuppressive Agents Phase 4,Phase 2,Phase 1
8 Tin Fluorides Phase 4
9 triamcinolone acetonide Phase 4,Phase 2
10 Triamcinolone diacetate Phase 4,Phase 2
11 Triamcinolone hexacetonide Phase 4,Phase 2
12 Keratolytic Agents Phase 4,Phase 2
13
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
14
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2, 11096-26-7
15
Ornithine Approved, Nutraceutical Phase 3,Phase 2 70-26-8, 3184-13-2 6262
16 Anti-Infective Agents Phase 3,Phase 1,Phase 2
17 Antiparasitic Agents Phase 3,Phase 2,Phase 1
18 Antiprotozoal Agents Phase 3,Phase 2,Phase 1
19 Hematinics Phase 3
20
Gefitinib Approved, Investigational Phase 1, Phase 2 184475-35-2 123631
21
Peginterferon alfa-2a Approved, Investigational Phase 1, Phase 2 198153-51-4 5360545
22
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
23
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
24
Aminolevulinic acid Approved Phase 2,Early Phase 1 106-60-5 137
25
Isotretinoin Approved Phase 2 4759-48-2 5282379 5538
26
Pembrolizumab Approved Phase 2 1374853-91-4
27
nivolumab Approved Phase 2 946414-94-4
28
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
29
Peginterferon alfa-2b Approved Phase 2 215647-85-1, 99210-65-8
30
Pioglitazone Approved, Investigational Phase 2 111025-46-8 4829
31
Everolimus Approved Phase 2 159351-69-6 6442177
32
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
33
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
34
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
35
Tretinoin Approved, Investigational, Nutraceutical Phase 2,Phase 1 302-79-4 5538
36
Levulinic acid Experimental Phase 2 123-76-2 11579
37
Lapatinib Approved March 2007, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
38 Antibodies Phase 2
39 Antibodies, Monoclonal Phase 2
40 Immunoglobulins Phase 2
41 Antiviral Agents Phase 1, Phase 2
42 Interferon-alpha Phase 1, Phase 2
43 interferons Phase 1, Phase 2
44 Protein Kinase Inhibitors Phase 1, Phase 2
45 Mitogens Phase 2
46
Erlotinib Hydrochloride Phase 2,Phase 1 183319-69-9 176871
47 Photosensitizing Agents Phase 2,Phase 1,Early Phase 1
48 Anti-Inflammatory Agents Phase 2
49 glucocorticoids Phase 2
50 Hormone Antagonists Phase 2

Interventional clinical trials:

(show top 50) (show all 85)

# Name Status NCT ID Phase Drugs
1 CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial Completed NCT00847912 Phase 4 5-fluorouracil;Placebo, vehicle control
2 Acitretin Plasma Levels Under Hemodialysis Suspended NCT00488384 Phase 4 Chemopreventive application (Acitretin)
3 Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy for Cancer of the Head and Neck Completed NCT00193895 Phase 3 Carboplatin
4 Eflornithine to Prevent Skin Cancer in Patients With Previously Treated Early Stage Skin Cancer Completed NCT00005884 Phase 3 eflornithine
5 Radiation Therapy in Treating Patients With Head and Neck Cancer Completed NCT00021125 Phase 3
6 Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Completed NCT01362140 Phase 3 Darbepoetin alfa;Placebo
7 Panitumumab (Vectibix®) in Cutaneous Squamous Cell Carcinoma (SCC) Unknown status NCT01129154 Phase 2 infusions of Panitumumab
8 Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer Unknown status NCT00423397 Phase 1, Phase 2 gefitinib
9 Low Fat Diet to Prevent Disease Progression in Patients With Skin Cancer Unknown status NCT00003097 Phase 2
10 Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer Completed NCT00126555 Phase 2 Gefitinib
11 Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia Completed NCT00563290 Phase 2 dasatinib
12 An Open-Label Safety Study of API 31510 in a Topical Cream for in Situ Cutaneous Squamous Cell Carcinoma (SCCIS) Completed NCT00652080 Phase 1, Phase 2 API 31510
13 Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Cutaneous Squamous Cell Carcinoma In Situ Completed NCT00329121 Phase 2 PEP005
14 Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR Completed NCT00240682 Phase 2 cetuximab
15 ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin Completed NCT00054691 Phase 2 Iressa
16 A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma Completed NCT00369512 Phase 2 Erlotinib
17 Clinical Study Assessment of SR-T100 Topical Gel Against Actinic Keratosis Completed NCT02085395 Phase 2 SR-T100 ® Gel
18 Photodynamic Therapy in Treating Patients With Skin Cancer Completed NCT00002963 Phase 2 aminolevulinic acid hydrochloride
19 Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis Completed NCT00021294 Phase 2 eflornithine;triamcinolone
20 Photodynamic Therapy in Treating Patients With Skin Cancer Completed NCT00002975 Phase 2 aminolevulinic acid
21 Investigation of a Behavioral Substitute for Sunbathing Completed NCT00403377 Phase 1, Phase 2
22 T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant Completed NCT00089180 Phase 2 liposomal T4N5 lotion
23 Oral Rigosertib for Squamous Cell Carcinoma Completed NCT01807546 Phase 2 rigosertib
24 SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck Completed NCT00006361 Phase 2 semaxanib
25 Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer Completed NCT00002506 Phase 2 isotretinoin
26 Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma Recruiting NCT02760498 Phase 2 REGN2810
27 Study of Pembrolizumab (MK-3475) in Adults With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) (MK-3475-629/KEYNOTE-629) Recruiting NCT03284424 Phase 2
28 Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer Recruiting NCT02964559 Phase 2
29 Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck Recruiting NCT01979211 Phase 2 Cetuximab
30 Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Recruiting NCT02978625 Phase 2
31 Cobimetinib and Atezolizumab in Advanced Rare Tumors Recruiting NCT03108131 Phase 2 Cobimetinib;Atezolizumab
32 Effect of Solanum Melongena Extract in the Treatment of Arsenical Skin Lesion Recruiting NCT03127670 Phase 2 Solanum melongena peel extract 0.05%
33 Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Recruiting NCT02721732 Phase 2 Pembrolizumab
34 Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma Recruiting NCT03082534 Phase 2 Pembrolizumab, Cetuximab
35 Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma Active, not recruiting NCT02218164 Phase 2 Pegylated Interferon alpha-2b;Capecitabine;5-FU
36 Efficacy and Safety of Dacomitinib in the Treatment of Skin Squamous Cell Cancer Active, not recruiting NCT02268747 Phase 2 Dacomitinib
37 Study of Pembrolizumab as First Line Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin Active, not recruiting NCT02883556 Phase 2 Pembrolizumab
38 Study of Erlotinib in the Treatment of Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC) of the Skin Active, not recruiting NCT01198028 Phase 2 Erlotinib
39 Preventing Squamous Cell Skin Cancer Enrolling by invitation NCT02347813 Phase 2 Pioglitazone
40 Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis) Not yet recruiting NCT03333694 Phase 1, Phase 2 Cutaneous Cream application;Placebo Cutaneous Cream application
41 Alpha Radiation Emitters Device for the Treatment of Squamous Cell Carcinoma (DaRT) Not yet recruiting NCT03353077 Phase 1, Phase 2
42 A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer Not yet recruiting NCT03327064 Phase 1, Phase 2 UAB30;Placebo
43 Sirolimus in Kidney Transplant Patients With Squamous Cell Skin Carcinoma Terminated NCT01764607 Phase 2 Sirolimus
44 Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin Terminated NCT01823679 Phase 2 Capecitabine
45 Treatment With Nab-paclitaxel in Cutaneous SCC Terminated NCT02076243 Phase 2 nab-paclitaxel
46 Green Tea Extract in Treating Patients With Actinic Keratosis Terminated NCT00005097 Phase 2 Polyphenon E and Placebo
47 Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin Terminated NCT01059305 Phase 2 Erlotinib
48 A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma Terminated NCT02050321 Phase 2 Acitretin;Vemurafenib
49 Single-center Investigator Initiated Pilot Study Investigating the Tumor Response of Squamous Cell Carcinoma Lesions in Patients Under Lapatinib Treatment Terminated NCT01666431 Phase 2 Lapatinib
50 Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC) Terminated NCT01984892 Phase 2 Poly-ICLC

Search NIH Clinical Center for Skin Squamous Cell Carcinoma

Genetic Tests for Skin Squamous Cell Carcinoma

Anatomical Context for Skin Squamous Cell Carcinoma

MalaCards organs/tissues related to Skin Squamous Cell Carcinoma:

38
Skin, Kidney, Lymph Node, Bone, Lung, Monocytes

Publications for Skin Squamous Cell Carcinoma

Articles related to Skin Squamous Cell Carcinoma:

(show top 50) (show all 69)
# Title Authors Year
1
Bromodomain protein BRD4 promotes cell proliferation in skin squamous cell carcinoma. ( 29050985 )
2018
2
Targeting sphingosine kinase 2 by ABC294640 inhibits human skin squamous cell carcinoma cell growth. ( 29428730 )
2018
3
Correlation Between Microvessel Density and Morphological Features in Skin Squamous Cell Carcinoma. ( 28593886 )
2017
4
Cancer cell of origin controls epithelial-to-mesenchymal transition in skin squamous cell carcinoma. ( 28607908 )
2017
5
Targeting PI3K-AKT-mTOR by LY3023414 inhibits human skin squamous cell carcinoma cell growth inA vitro and inA vivo. ( 28623128 )
2017
6
CCR5-dependent homing of T regulatory cells to the tumor microenvironment contributes to skin squamous cell carcinoma development. ( 28904130 )
2017
7
Antimicrobial peptide LL-37 promotes the viability and invasion of skin squamous cell carcinoma by upregulating YB-1. ( 28672959 )
2017
8
Quantitative phosphoproteomic analysis reveals system-wide signaling pathways regulated by site-specific phosphorylation of Keratin-8 in skin squamous cell carcinoma derived cell line. ( 28176443 )
2017
9
A case report of Muir-Torre syndrome in a woman with breast cancer and MSI-Low skin squamous cell carcinoma. ( 28507641 )
2017
10
Lgr6 is a stem cell marker in mouse skin squamous cell carcinoma. ( 28945253 )
2017
11
DC vaccine generated by ALA-PDT-induced immunogenic apoptotic cells for skin squamous cell carcinoma. ( 27471605 )
2016
12
The genetic evolution of skin squamous cell carcinoma: tumor suppressor identity matters. ( 27193637 )
2016
13
Antimicrobial peptide LL-37 promotes the proliferation and invasion of skin squamous cell carcinoma by upregulating DNA-binding protein A. ( 27588122 )
2016
14
Erratum: Genomic landscape of carcinogen-induced and genetically induced mouse skin squamous cell carcinoma. ( 26845409 )
2016
15
Predicted cases of U.K. skin squamous cell carcinoma and basal cell carcinoma in 2020 and 2025: horizon planning for National Health Service dermatology and dermatopathology. ( 27714753 )
2016
16
Inhibitory effect of berberine on human skin squamous cell carcinoma A431 cells. ( 26400287 )
2015
17
Efficacy of elective nodal irradiation in skin squamous cell carcinoma of the face, ears, and scalp. ( 26391010 )
2015
18
Autophagy in human skin squamous cell carcinoma: Inhibition by 3-MA enhances the effect of 5-FU-induced chemotherapy sensitivity. ( 26398820 )
2015
19
Improvement of DC vaccine with ALA-PDT induced immunogenic apoptotic cells for skin squamous cell carcinoma. ( 25915530 )
2015
20
TIPE2 regulates tumor-associated macrophages in skin squamous cell carcinoma. ( 26577853 )
2015
21
Genomic landscape of carcinogen-induced and genetically induced mouse skin squamous cell carcinoma. ( 26168291 )
2015
22
Ginsenoside rh2 inhibits cancer stem-like cells in skin squamous cell carcinoma. ( 25966742 )
2015
23
Inhibition of skin squamous cell carcinoma proliferation and promote apoptosis by dual silencing of NET-1 and survivin. ( 26080853 )
2015
24
Skin squamous cell carcinoma presenting as cellulitis. ( 25635168 )
2015
25
Exposure to moxifloxacin and cytomegalovirus replication is associated with skin squamous cell carcinoma development in lung transplant recipients. ( 26403508 )
2015
26
Inhibitory effect of curcumin on invasion of skin squamous cell carcinoma a431 cells. ( 25854367 )
2015
27
Clinical significance of STAT3 and MAPK phosphorylation, and the protein expression of cyclin D1 in skin squamous cell carcinoma tissues. ( 26497194 )
2015
28
Aldo-keto reductase 1C3 is overexpressed in skin squamous cell carcinoma (SCC) and affects SCC growth via prostaglandin metabolism. ( 24917395 )
2014
29
Lgr5-positive cells are cancer stem cells in skin squamous cell carcinoma. ( 25135431 )
2014
30
Advanced skin squamous cell carcinoma: role of radiotherapy. ( 24563891 )
2014
31
Lung transplant recipients receiving voriconazole and skin squamous cell carcinoma risk in Australia. ( 25358582 )
2014
32
Sox2, a marker for stem-like tumor cells in skin squamous cell carcinoma and hedgehog subgroup medulloblastoma. ( 25061226 )
2014
33
Clinical significance of methylation of E-cadherin and p14ARF gene promoters in skin squamous cell carcinoma tissues. ( 25126184 )
2014
34
The inhibition of resveratrol to human skin squamous cell carcinoma A431 xenografts in nude mice. ( 23428654 )
2013
35
HPV type 16-induced skin squamous cell carcinoma located on the groin of immunocompetent patients. ( 24116660 )
2013
36
Expression and function of NET-1 in human skin squamous cell carcinoma. ( 24196235 )
2013
37
Immunohistochemical analysis of O(6)-methylguanine-DNA methyltransferase in human melanoma in comparison with skin squamous cell carcinoma. ( 23460078 )
2013
38
Tetraspanin CD151 plays a key role in skin squamous cell carcinoma. ( 22824799 )
2013
39
Upregulation of TCTP expression in human skin squamous cell carcinoma increases tumor cell viability through anti-apoptotic action of the protein. ( 22969908 )
2012
40
Skin squamous cell carcinoma propagating cells increase with tumour progression and invasiveness. ( 23188079 )
2012
41
Pronounced allelic imbalance at D9S162 in skin squamous cell carcinoma of organ transplant recipients. ( 22508773 )
2012
42
Involvement of VILIP-1 (visinin-like protein) and opposite roles of cyclic AMP and GMP signaling in in vitro cell migration of murine skin squamous cell carcinoma. ( 21480386 )
2011
43
The incidence of skin squamous cell carcinoma in Osijek-Baranja County--an epidemiological study. ( 22220409 )
2011
44
Curcumin inhibits skin squamous cell carcinoma tumor growth in vivo. ( 21493306 )
2011
45
C/EBPI+ expression is downregulated in human nonmelanoma skin cancers and inactivation of C/EBPI+ confers susceptibility to UVB-induced skin squamous cell carcinomas. ( 21346772 )
2011
46
Immune phenotype of peripheral blood cells and skin squamous cell carcinoma in organ transplant recipients. ( 20441422 )
2010
47
Association of the DSS1 c.143G>A polymorphism with skin squamous cell carcinoma. ( 20220765 )
2010
48
[Expression, clinical and pathological significance of KIAA1173 gene in skin squamous cell carcinoma]. ( 20646595 )
2010
49
Desipramine inhibits the growth of a mouse skin squamous cell carcinoma cell line and affects glucocorticoid receptor-mediated transcription. ( 19575421 )
2009
50
Etretinate enhances the susceptibility of human skin squamous cell carcinoma cells to 5-aminolaevulic acid-based photodynamic therapy. ( 19077103 )
2009

Variations for Skin Squamous Cell Carcinoma

ClinVar genetic disease variations for Skin Squamous Cell Carcinoma:

6 (show all 23)
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
2 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
3 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121912657 GRCh37 Chromosome 17, 7577124: 7577124
4 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Pathogenic/Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
5 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
6 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
7 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
8 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
9 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913357 GRCh37 Chromosome 7, 140481403: 140481403
10 BRAF NM_004333.4(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
11 BRAF NM_004333.4(BRAF): c.1406G> A (p.Gly469Glu) single nucleotide variant Pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
12 HRAS NM_005343.3(HRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
13 BRAF NM_004333.4(BRAF): c.1406G> T (p.Gly469Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
14 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587780070 GRCh37 Chromosome 17, 7578395: 7578395
15 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893
16 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic/Likely pathogenic rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
17 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
18 TP53 NM_000546.5(TP53): c.706T> G (p.Tyr236Asp) single nucleotide variant Pathogenic/Likely pathogenic rs587782289 GRCh37 Chromosome 17, 7577575: 7577575
19 HRAS NM_005343.3(HRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs104894226 GRCh38 Chromosome 11, 534285: 534285
20 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh38 Chromosome 17, 7673778: 7673778
21 TP53 NM_000546.5(TP53): c.856G> A (p.Glu286Lys) single nucleotide variant Pathogenic/Likely pathogenic rs786201059 GRCh37 Chromosome 17, 7577082: 7577082
22 TP53 NM_000546.5(TP53): c.833C> T (p.Pro278Leu) single nucleotide variant Pathogenic/Likely pathogenic rs876659802 GRCh37 Chromosome 17, 7577105: 7577105
23 TP53 NM_000546.5(TP53): c.638G> C (p.Arg213Pro) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211

Cosmic variations for Skin Squamous Cell Carcinoma:

9 (show top 50) (show all 3347)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM703213 ZNF668 skin,NS,carcinoma,squamous cell carcinoma c.1817C>T p.P606L 13
2 COSM4990873 ZNF668 skin,NS,carcinoma,squamous cell carcinoma c.878C>T p.S293L 13
3 COSM4990875 ZNF668 skin,NS,carcinoma,squamous cell carcinoma c.247C>T p.P83S 13
4 COSM4990309 ZMYM2 skin,NS,carcinoma,squamous cell carcinoma c.946C>T p.Q316* 13
5 COSM4990310 ZMYM2 skin,NS,carcinoma,squamous cell carcinoma c.946C>T p.Q316* 13
6 COSM4991869 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.282C>G p.A94A 13
7 COSM4991865 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.522C>T p.F174F 13
8 COSM4991861 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.876G>C p.P292P 13
9 COSM4991863 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.569A>C p.K190T 13
10 COSM4991867 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.314T>G p.V105G 13
11 COSM4990301 ZIC2 skin,NS,carcinoma,squamous cell carcinoma c.915G>A p.E305E 13
12 COSM3184673 ZFP36L2 skin,NS,carcinoma,squamous cell carcinoma c.569C>T p.P190L 13
13 COSM3184669 ZFP36L2 skin,NS,carcinoma,squamous cell carcinoma c.596C>T p.T199I 13
14 COSM4991542 ZBED4 skin,NS,carcinoma,squamous cell carcinoma c.328C>T p.R110W 13
15 COSM4993525 ZBED1 skin,NS,carcinoma,squamous cell carcinoma c.601T>G p.W201G 13
16 COSM4991780 XPO1 skin,NS,carcinoma,squamous cell carcinoma c.2285G>A p.W762* 13
17 COSM4991846 XPC skin,NS,carcinoma,squamous cell carcinoma c.2446G>A p.E816K 13
18 COSM4991849 XPC skin,NS,carcinoma,squamous cell carcinoma c.2254C>T p.P752S 13
19 COSM4829120 XPC skin,NS,carcinoma,squamous cell carcinoma c.1439C>T p.S480F 13
20 COSM4991848 XPC skin,NS,carcinoma,squamous cell carcinoma c.2255C>T p.P752L 13
21 COSM4991847 XPC skin,NS,carcinoma,squamous cell carcinoma c.2445G>A p.E815E 13
22 COSM4990181 WT1 skin,NS,carcinoma,squamous cell carcinoma c.726C>A p.N242K 13
23 COSM4990704 VTI1B skin,NS,carcinoma,squamous cell carcinoma c.274C>T p.H92Y 13
24 COSM4991824 UMPS skin,NS,carcinoma,squamous cell carcinoma c.332G>A p.G111E 13
25 COSM4991823 UMPS skin,NS,carcinoma,squamous cell carcinoma c.331G>A p.G111R 13
26 COSM4991826 UMPS skin,NS,carcinoma,squamous cell carcinoma c.843G>A p.K281K 13
27 COSM4990646 TTLL7 skin,NS,carcinoma,squamous cell carcinoma c.1501-1G>A p.? 13
28 COSM4990645 TTLL7 skin,NS,carcinoma,squamous cell carcinoma c.1501G>A p.E501K 13
29 COSM4990647 TTLL7 skin,NS,carcinoma,squamous cell carcinoma c.1001G>A p.G334E 13
30 COSM4990715 TSHR skin,NS,carcinoma,squamous cell carcinoma c.91T>C p.C31R 13
31 COSM3498383 TSHR skin,NS,carcinoma,squamous cell carcinoma c.1248C>T p.F416F 13
32 COSM4990717 TSHR skin,NS,carcinoma,squamous cell carcinoma c.171-1G>A p.? 13
33 COSM4990721 TSHR skin,NS,carcinoma,squamous cell carcinoma c.693-1G>A p.? 13
34 COSM4990719 TSHR skin,NS,carcinoma,squamous cell carcinoma c.492G>A p.M164I 13
35 COSM4990722 TSHR skin,NS,carcinoma,squamous cell carcinoma c.937A>T p.K313* 13
36 COSM4990723 TSHR skin,NS,carcinoma,squamous cell carcinoma c.1459G>A p.D487N 13
37 COSM4606358 TSC2 skin,NS,carcinoma,squamous cell carcinoma c.1378G>A p.A460T 13
38 COSM4990848 TSC2 skin,NS,carcinoma,squamous cell carcinoma c.1846G>A p.D616N 13
39 COSM4990850 TSC2 skin,NS,carcinoma,squamous cell carcinoma c.2587G>A p.E863K 13
40 COSM4423739 TSC2 skin,NS,carcinoma,squamous cell carcinoma c.2615C>T p.S872F 13
41 COSM4990854 TSC2 skin,NS,carcinoma,squamous cell carcinoma c.2707C>T p.P903S 13
42 COSM4990856 TSC2 skin,NS,carcinoma,squamous cell carcinoma c.3330C>T p.A1110A 13
43 COSM4990845 TSC2 skin,NS,carcinoma,squamous cell carcinoma c.1153C>T p.H385Y 13
44 COSM4993227 TSC1 skin,NS,carcinoma,squamous cell carcinoma c.2880G>A p.L960L 13
45 COSM4993232 TSC1 skin,NS,carcinoma,squamous cell carcinoma c.1993A>G p.N665D 13
46 COSM4993230 TSC1 skin,NS,carcinoma,squamous cell carcinoma c.2640G>A p.M880I 13
47 COSM4993229 TSC1 skin,NS,carcinoma,squamous cell carcinoma c.2750C>T p.A917V 13
48 COSM4993231 TSC1 skin,NS,carcinoma,squamous cell carcinoma c.2208+1G>A p.? 13
49 COSM4993226 TSC1 skin,NS,carcinoma,squamous cell carcinoma c.2881G>A p.E961K 13
50 COSM4993228 TSC1 skin,NS,carcinoma,squamous cell carcinoma c.2751C>T p.A917A 13

Expression for Skin Squamous Cell Carcinoma

Search GEO for disease gene expression data for Skin Squamous Cell Carcinoma.

Pathways for Skin Squamous Cell Carcinoma

Pathways related to Skin Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.41 BRAF EIF4E HRAS IFNA1 IL10 NET1
2
Show member pathways
12.88 EIF4E HRAS IFNA1 STAT1 STAT2 TP53
3
Show member pathways
12.77 BIRC5 BRAF EIF4E HRAS IFNA1 IL10
4 12.52 BIRC5 BRAF HRAS IFNA1 STAT1 STAT2
5
Show member pathways
12.5 BIRC5 HRAS IL10 STAT1 TP53
6
Show member pathways
12.4 BRAF HRAS STAT1 TP53
7
Show member pathways
12.34 BRAF HRAS STAT1 STAT2 TP53
8
Show member pathways
12.32 BIRC5 HRAS IFNA1 STAT1 STAT2 TP53
9
Show member pathways
12.31 BIRC5 HRAS STAT1 TP53
10
Show member pathways
12.17 BRAF HRAS STAT1 TP53
11
Show member pathways
12.17 BRAF EIF4E HRAS STAT1 STAT2
12
Show member pathways
12.15 HRAS IFNA1 IL10 STAT1 STAT2
13
Show member pathways
12.11 EIF4E IFNA1 NET1 STAT1 STAT2
14 12.09 BIRC5 BRAF STAT1 TP53
15
Show member pathways
12.04 BRAF HRAS STAT1 TP53
16
Show member pathways
12.02 IFNA1 IL10 STAT1 STAT2
17
Show member pathways
11.94 EIF4E HRAS STAT1 TP53
18 11.84 BIRC5 IL10 STAT1 TP53
19 11.8 BRAF HRAS MGMT TP53
20 11.71 BIRC5 EIF4E TP53
21 11.64 BRAF HRAS TP53
22 11.61 BRAF HRAS STAT1
23 11.51 EIF4E STAT1 STAT2
24 11.46 HRAS IFNA1 IL10 STAT1 STAT2
25 11.36 BIRC5 HRAS STAT1
26 11.22 BRAF HRAS IFNA1 STAT1 STAT2 TP53

GO Terms for Skin Squamous Cell Carcinoma

Biological processes related to Skin Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.8 BIRC5 BRAF IL10 MGMT TP53
2 negative regulation of inflammatory response GO:0050728 9.61 IL10 KLF4 TNFAIP8L2
3 cellular response to organic cyclic compound GO:0071407 9.5 KLF4 MGMT STAT1
4 type I interferon signaling pathway GO:0060337 9.43 IFNA1 STAT1 STAT2
5 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.37 IL10 KLF4
6 regulation of axon regeneration GO:0048679 9.16 BRAF KLF4
7 cellular response to ionizing radiation GO:0071479 9.13 MGMT NET1 TP53
8 regulation of type I interferon-mediated signaling pathway GO:0060338 8.8 IFNA1 STAT1 STAT2

Molecular functions related to Skin Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription cofactor binding GO:0001221 8.62 KLF4 TP53

Sources for Skin Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....